Galmed Pharmaceuticals Ltd. has announced that it has received a new patent for the use of Aramchol, its lead drug, in combination with Rezdiffra (also called Resmetirom) to treat NASH (non-alcoholic steatohepatitis) or MASH (metabolic dysfunction-associated steatohepatitis) and liver fibrosis in South Korea. This new patent extends the protection of Aramchol until 2042, building up its position in the field of liver disease treatments.
Galmed has been focusing on developing Aramchol primarily for liver diseases and is continuing to operate on its combination therapy for NASH. The company is also exploring new uses for Aramchol in other areas, such as cancer treatments, and is actively looking to expand its product portfolio to include other cardiometabolic conditions as well as innovative drug candidates.
This new patent marks a significant milestone for Galmed Pharmaceuticals as it continues to advance its efforts in liver disease treatments. The combination of Aramchol and Rezdiffra offers hope for more effective therapies for MASH and NASH, diseases with limited treatment options. Galmed's focus on combination therapies reflects its commitment to addressing complex medical conditions with greater precision and efficacy.
Executive Statement
According to Allen Baharaff, CEO of Galmed Pharmaceuticals, this patent grant comes at a pivotal moment in the NASH/MASH field, as the industry shifts toward combination therapies to address this complex disease. As commercial interest in MASH is surging, with the limited mild to moderate efficacy demonstrated by monotherapies, initiation of combination MASH clinical studies is necessary and imminent. They believe Aramchol's excellent safety and tolerability is a perfect drug candidate to be combined with other MASH drugs, approved or in development. The grant of the Aramchol – Rezdiffra new patent is an important step towards the advancement in this direction.